Valeant Pharmaceuticals International, Inc.
15.33 -0.30(-1.92%) Date:
Analysts would eye the upcoming earnings due later this month, while the company is expected to give a lower guidance amid recent developments
Takeda has recently finalized the acquisition of cancer drugmaker ARIAD Pharmaceuticals for $5.2 billion
Valeant's recent divestitures will dramatically reduce its debt and provide management with ample to steer the company toward growth trajectory
Canaccord Genuity raises target price but maintains HOLD rating
It won't be wrong to say that the Laval based-company is slowly nearing its end as it continues to sell off business units